NCT04173637View on ClinicalTrials.gov

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

330

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

March 3, 2022

Study Completion Date

March 3, 2022

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL

AK101

an anti-IL-12/23p40 monoclonal antibody

BIOLOGICAL

Placebo

matching placebo

Trial Locations (2)

100730

Peking Union Medical College Hospital, Beijing

Peking University People's Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Akeso Tiancheng, Inc

OTHER

lead

Akeso

INDUSTRY

NCT04173637 - Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter